Breast Surgeons Live
Back to Activities List
Session Title:
Imaging Adjuncts and Updates for High-Risk Populations
Date & Time:
January 08, 2025, 7:00 PM–8:00 PM ET
Length:
1 Hour
CME Deadline:
January 8, 2026
Log in to access members-only content.
Target Audience:
Surgeons with a special interest in the treatment of breast disease.
Objectives:
At the end of this activity, participants will be able to:
- Recommend supplemental screening with understanding of available imaging modalities (ie CEM, FAST MRI).
- Summarize breast density reporting laws and articulate the status of insurance coverage for supplemental screening.
- Distinguish between high versus moderate penetrance pathogenic variant gene mutations, and estimate contralateral breast cancer risk.
Description:
This webinar is intended for all breast team members who participate in high-risk breast screening & counseling. Discussion will focus on supplemental screening options, legislation regarding breast cancer screening and finish with a discussion on the impact of moderate penetrance pathogenic variants on contralateral breast cancer risk and recommendations.
Agenda:
Welcome and Introduction
Brittany Murphy, MD, MS, FACS, and Melissa Pilewskie, MD
Breast Density: FDA Regulations on Reporting, Impact on Risk of Breast Cancer, and Supplemental Screening Options
Onalisa Winblad, MD
Imaging Modalities for Supplemental & High-Risk Screening
Jennifer Plichta, MD, MS
Impact of Pathogenic Genetic Variants on Breast Cancer Risk in Unaffected Versus Affected Patients?
Siddhartha Yadav, MD, FACP
Panel Discussion With Q&A
Faculty:
Moderator—Brittany Murphy, MD, MS, FACS
Banner MD Anderson Cancer Center
Gilbert, AZ
Moderator—Melissa Pilewskie, MD
University of Michigan
Ann Arbor, MI
Jennifer Plichta, MD, MS
Duke University
Durham, NC
Onalisa Winblad, MD
The University of Kansas Health System
Leawood, KS
Siddhartha Yadav, MD, FACP
Mayo Clinic
Rochester, MN
References:
- Cappello, N.M., D. Richetelli, and C.I. Lee, The Impact of Breast Density Reporting Laws on Women's Awareness of Density-Associated Risks and Conversations Regarding Supplemental Screening With Providers. J Am Coll Radiol, 2019. 16(2): p. 139-146.
- Huang, S., et al., The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review. Breast Cancer Res Treat, 2021. 187(1): p. 11-30.
- Kressin, N.R., P.J. Slanetz, and C.M. Gunn, Ensuring Clarity and Understandability of the FDA's Breast Density Notifications. JAMA, 2023. 329(2): p. 121-122.
- Vegunta, S., J.M. Kling, and B.K. Patel, Supplemental Cancer Screening for Women With Dense Breasts: Guidance for Health Care Professionals. Mayo Clin Proc, 2021. 96(11): p. 2891-2904.
- Bedrosian, I., et al., Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol, 2024. 42(5): p. 584-604.
- Yadav, S., et al., Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol, 2023. 41(9): p. 1703-1713.
Disclosures:
coming soon
